Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
Florent Ferrer, Pauline Tétu, L. Dousset, Célèste Lebbé, Joseph Ciccolini, David Combarel, Nicolás Meyer, Angélo Paci, Stéphane Bouchet
Topics & Concepts
DosingMedicinePharmacokineticsAdverse effectDrugTyrosine-kinase inhibitorPharmacologyQuality of life (healthcare)Intensive care medicinePharmacogeneticsOncologyInternal medicineCancerNursingChemistryGenotypeGeneBiochemistryChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchHER2/EGFR in Cancer Research